ANNALS OF THE RHEUMATIC DISEASES, published by BMJ Publishing Group, stands as a leading academic journal in the realm of rheumatology and related fields, including biochemistry, immunology, and genetics. With an esteemed impact factor and a consistent ranking in the upper echelons of its category (Q1) as per the latest evaluations, this journal represents the forefront of research and innovation, fostering scientific advancement from 1945 to the present. As the top journal in the Medicine - Rheumatology category and achieving remarkable percentiles in various interdisciplinary categories, it serves as a critical platform for researchers, clinicians, and students dedicated to understanding and addressing rheumatic diseases. Although it does not currently offer open access, its rigorous peer-review process ensures the dissemination of high-quality research findings that are paramount in enhancing clinical practices and advancing scientific discourse. Readers can expect to be challenged and inspired by the breadth of studies and reviews that address the complexities of rheumatology and its intersecting scientific domains.

Advances in Rheumatology is a premier open-access journal published by BMC, dedicated to advancing the field of rheumatology through high-quality, peer-reviewed research. Launched in 2018, the journal has quickly established itself within the academic community, achieving a commendable Q2 ranking in the category of Rheumatology as of 2023 and ranking #34 out of 73 in the Scopus Medicine Rheumatology listings, placing it in the 54th percentile. With a focus on innovative treatments, patient care, and the latest in rheumatological research, the journal provides a platform for researchers and clinicians to disseminate their findings and foster collaborative advancements in this critical area of medicine. Recognized for its accessibility, the journal follows an open-access model, ensuring that research is freely available to a global audience. With a commitment to high standards of academic rigor, Advances in Rheumatology plays a vital role in enhancing the understanding and treatment of rheumatic diseases, making it an invaluable resource for researchers, professionals, and students alike.

Epilepsy Currents, published by SAGE Publications Inc, is a vital scholarly journal dedicated to the field of neurology, specifically focusing on epilepsy and seizure-related disorders. With its ISSN 1535-7597 and E-ISSN 1535-7511, the journal aims to disseminate high-quality research, reviews, and clinical insights that contribute to the understanding and management of epilepsy. Boasting a Q3 ranking in clinical neurology for the year 2023, it is positioned among the noteworthy academic resources available to professionals and researchers alike, with its Scopus rank placing it within the 36th percentile of its category. Despite its current non-open access status, the journal remains an essential repository of knowledge for those looking to deepen their expertise in neurology and to stay abreast of the latest developments in the field. Operating out of Thousand Oaks, California, Epilepsy Currents emphasizes evidence-based practices and innovative approaches, encouraging an active dialogue within the academic community and ensuring its ongoing relevance as it converges from 2011 to 2024.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.

The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

HEADACHE is a premier academic journal dedicated to advancing the study of headache disorders through innovative research and clinical insights. Published by WILEY, this influential journal has been serving the neurology community since its inception in 1961 and is recognized as a leader in its field, boasting an impressive Q1 ranking in both Neurology and Neurology (clinical) categories for 2023. With a robust Scopus ranking of #48 in clinical neurology and #26 in neuroscience, HEADACHE consistently publishes high-quality research that contributes to the understanding and treatment of headache disorders worldwide. Although it does not offer open access options, the journal remains accessible to a wide audience through various institutional subscriptions. It aims to provide a platform for researchers, healthcare professionals, and students to exchange ideas and develop new strategies for headache management, making it an essential resource for those dedicated to improving patient outcomes in this challenging area of healthcare.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.